Roundhill NVDA WeeklyPay ETF vs GeneDx Holdings Corp — how do they compare? Roundhill NVDA WeeklyPay ETF trades at $36.03, while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). Which is the better fit depends on your goals.
| NVDW | WGS | |
|---|---|---|
Sector | Income / Options Overlay | Technology |
52-Week High | $53.42 | $167.51 |
52-Week Low | $31.88 | $34.51 |
Market Cap | — | $1.80B |
Enterprise Value | — | $1.80B |
Signals from Pluang's Aura AI — not financial advice
NVDW trades at $35.2, down 1.1% for the day, with a strong bearish technical signal from moving averages. The stock exhibits a high-dividend profile with frequent payouts, though the yield is variable. Recent coverage highlights its role as a quasi-synthetic leveraged play on Nvidia, offering significant income generation potential.
The outlook is mixed, balancing a high-yield income stream against technical weakness and dependency on Nvidia's performance. Key risks include payout volatility and concentrated exposure. The investment case hinges on income generation amid a bearish trend.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Trailing returns across standard periods
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →